Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis is supported by a lead asset, envudeucitinib, that has already shown deepening efficacy over time, quality-of-life gains, itch relief, scalp psoriasis benefit, and a well-tolerated safety profile in phase III psoriasis data, while its more consistent PASI 100 responses in a difficult-to-treat population strengthen its competitive position versus zasocitinib. The company’s 3Q26 SLE readout is the next major catalyst, and positive results from the ongoing global phase IIb trial in 408 patients could validate the pipeline-in-a-pill thesis, de-risk expansion beyond psoriasis, and support partnering discussions in a market with no approved oral targeted therapy for SLE. With updated 1Q26 financials already incorporated into the outlook and additional longer-term durability and safety data expected in 2H26, the stock’s fundamentals appear increasingly derisked and strategically attractive.

Alumis is facing a weakened fundamental profile because Envudeucitinib’s Phase IIb SLE study in 408 patients missed both primary and secondary endpoints in the overall population, leaving the company dependent on post-hoc IFNG-high subgroup signals that do not yet de-risk the program. The high 47.5% placebo response in BICLA suggests the result may reflect small-sample noise or trial skew rather than robust efficacy, while the next step toward Phase III still carries regulatory uncertainty and likely a 2-3 year development path. Meanwhile, the company remains exposed to execution, competition, and financing risk across its TYK2 pipeline, including a Phase I readout for A-005, with potential dilution before it reaches profitability.